Drug Type Gene editing |
Synonyms |
Target |
Mechanism DMD exon 53 inhibitors(Dystrophin exon 53 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Preclinical | CN | 12 Jun 2024 |